Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Definium Therapeutics Full Year 2025 Earnings Call - DT120 Phase 3 Readouts Imminent; Emerge (MDD) Late Q2, Voyage (GAD) Early Q3, Cash into 2028
Definium heads into a make-or-break 2026 with DT120 ODT front and center. Emerge, the first pivotal MDD trial, is fully enrolled with topline due late Q2, Voyage (GAD) is roughly 80% enrolled with top...
- DT120 ODT is the companys lead program with three Phase 3 readouts expected in 2026; Emerge (MDD) is fully enrolled and topline is expected late Q2 2026.
- Voyage (GAD) is approximately 80% enrolled, completed a blinded sample size re-estimation with no increase required, and topline is expected early Q3 2026.
- Panorama (second GAD pivotal) is enrolling rapidly, includes European sites, and management will disclose its blinded sample size re-estimation and further enrollment details at Analyst Day in April.
- +12 more takeaways
TeraWulf Q4 & FY2025 Earnings Call - Pivoting from Mining to Power‑Backed AI Infrastructure with Google‑Backed 450 MW Lease
TeraWulf spent 2025 deliberately remaking itself. The company bought Beowulf Electricity & Data, closed long-duration site control deals (Cayuga, Kentucky, Morgantown/Chesapeake) and signed credit-enh...
- 2025 was a structural year: TeraWulf acquired Beowulf Electricity & Data to internalize power generation expertise and remove related‑party complexity.
- Signature commercial validation: a 450 MW lease with Fluidstack is credit‑enhanced by Google, and Google warrants will make it the company’s largest shareholder.
- Site control and brownfield strategy emphasized: Cayuga offers up to 400 MW at a retired coal facility; Morgantown (Chesapeake) is being engineered as a net generator, targeting ~500 MW of new dispatchable generation, 250 MW battery storage and 500 MW of data center load in phase one.
- +12 more takeaways
Talen Energy Corporation Q4 2025 Earnings Call - Reaffirmed 2026 Guidance While Pressing the 'Flywheel' on Data Center Power and Closing Cornerstone
Talen closed 2025 with stronger-than-expected results and opened 2026 by reaffirming guidance, leaning into a strategy to convert merchant generation into contracted infrastructure for data centers. M...
- Company reaffirmed 2026 guidance: adjusted EBITDA $1.75 billion to $2.05 billion, adjusted free cash flow $980 million to $1.18 billion.
- 2025 reported adjusted EBITDA of $1.035 billion and adjusted free cash flow of $524 million, both above prior guidance ranges.
- Q4 2025 results: adjusted EBITDA $382 million and adjusted free cash flow $292 million, with Q4 AFFCF exceeding full-year 2024.
- +12 more takeaways
Solventum Q4 2025 Earnings Call - Gaining Momentum Despite Separation Headwinds, Accelerating Toward Long-Range Targets
Solventum closed its first full year as a standalone company with visible commercial momentum, reporting $2.0 billion in Q4 sales, 3.5% organic growth for the quarter and 3.3% organic growth for the f...
- Q4 sales were $2.0 billion, up 3.5% organic in the quarter and down 3.7% reported due to the P&F divestiture and Acera acquisition effects.
- Full-year 2025 organic sales growth was 3.3%, normalized to roughly 3.5% after adjusting for SKU exits and dental backorder improvement.
- MedSurg and Dental outperformed in Q4; MedSurg organic +3.2% and Dental organic +5.9% (but Dental normalized closer to 3% after backorder benefit).
- +13 more takeaways
Syndax Pharmaceuticals Q4 2025 Earnings Call - Two launches fuel $172M year, Revuforj NPM1 ramp and axatilimab IPF readout set the bar for 2026
Syndax closed 2025 as a commercial biotech in earnest, delivering $172.4 million in revenue driven by two launches. Revuforj generated $124.8 million in its first full year and accelerated in Q4 as th...
- Syndax reported $172.4 million total revenue in 2025, comprised of $124.8 million Revuforj net revenue, $42.4 million Niktimvo collaboration revenue, and $5.1 million milestones/royalties.
- Revuforj accelerated in Q4 with $44.2 million in net revenue, up 38% sequentially, and total prescriptions increased about 35% quarter over quarter.
- Approximately 1,050 patients have been treated commercially with Revuforj since launch, and Syndax estimates near 50% penetration of the KMT2A incident population within the first year.
- +12 more takeaways
Crinetics Pharmaceuticals Q4 2025 Earnings Call - PALSONIFY launch gains traction as company pivots to a commercial-stage endocrinology franchise
Crinetics closed 2025 as a commercial-stage company, with PALSONIFY driving an early U.S. launch while the pipeline advances. Q4 product revenue was $5.4 million, enrollment activity accelerated with ...
- PALSONIFY commercial launch underway: Q4 net product revenue of $5.4 million, contributing to Q4 total net revenue of $6.2 million and FY 2025 revenue of $7.7 million.
- Launch traction metrics: more than 200 enrollment forms in Q4 and prescriptions from over 125 unique prescribers across community and pituitary centers.
- Payer access early momentum: management reports formulary wins with several major plans, straightforward prior authorizations aligned to label language and no onerous step edits so far; medical exceptions being used for broader coverage.
- +11 more takeaways
PubMatic Q4 2025 Earnings Call - Agentic AI Leadership Sparks Inflection, Sets Stage for Double-Digit H2 2026 Growth
PubMatic says Q4 marked a structural inflection: revenue and adjusted EBITDA beat expectations, driven by CTV, mobile app, and rapidly scaling AI products. Management highlighted AgenticOS and Activat...
- Q4 and full-year 2025 marked an inflection: PubMatic beat guidance on revenue and adjusted EBITDA, reporting Q4 adjusted EBITDA of $27.8M, a 35% margin.
- Management repeatedly flagged agentic AI as the defining secular tailwind; AgenticOS and Agentic campaigns are core strategic differentiators being scaled.
- Agentic adoption: PubMatic has run over 250 agentic deals, launched an Agentic AI Accelerator with ~100 applicants, and reports early proof points including a 5x campaign cost efficiency.
- +13 more takeaways
Emergent BioSolutions Q4 2025 Earnings Call - Transformation Slashes Leverage to 1.9x as Adjusted EBITDA Hits $205M
Emergent spent 2025 executing a clear turnaround, trading revenue tailwinds for a leaner, more profitable company. Adjusted EBITDA rose to $205 million, gross margin expanded roughly 900 basis points,...
- Adjusted EBITDA rose to $205 million in 2025, a 12% year-over-year increase and above prior guidance.
- Net leverage improved to 1.9x at year-end 2025, down from 3.3x at December 2024 and 5.7x in Q1 2024.
- Year-end cash was $205 million, with total liquidity of $305 million including a $100 million undrawn revolver.
- +12 more takeaways
VTEX Q4 2025 Earnings Call - AI-driven productivity lifts margins as sales cycles elongate
VTEX says 2025 was a test but not a structural failure. Growth came in below long-term ambition, driven by tougher consumer markets in Brazil and Argentina, a promotional marketplace backdrop, and an ...
- Management frames 2025 slowdown as cyclical, not structural, blaming Brazil and Argentina macro weakness, promotional marketplace dynamics in Brazil, and an "AI wait and see" that lengthened decision cycles.
- Q4 GMV was $6.3 billion, up 17.2% year-over-year in USD and 10.0% FX-neutral; full-year GMV was $20.5 billion, up 12.1% USD and 12.9% FX-neutral.
- Q4 subscription revenue was $66.7 million, +12.2% year-over-year in USD and +5.4% FX-neutral; full-year subscription revenue was $234.9 million, +7.9% USD and +9.5% FX-neutral.
- +12 more takeaways
Progyny, Inc. Q4 2025 Earnings Call - Record 2025 Results and Push into Fully Insured Small-Group Market
Progyny closed 2025 with a clean, loud line: record revenue of $1.29 billion and adjusted EBITDA of $222 million, and they converted that into a record $210 million of operating cash flow. Management ...
- 2025 was a record year: $1.29 billion revenue and $222 million adjusted EBITDA, both double-digit improvements over 2024.
- Operating cash flow hit a record $210 million in 2025, up 17% year-over-year; company emphasizes high conversion of adjusted EBITDA to cash.
- Q4 and full-year results consistently beat prior guidance, with Q4 revenue above the top end of the range by about $11 million.
- +13 more takeaways